Review Article

An Overview of Systematic Reviews of Using Chinese Medicine to Treat Polycystic Ovary Syndrome

Table 8

GRADE quality-of-evidence ratings for luteinizing hormone level.

Included systematic reviewsNumber of studies includedLuteinizing hormone effect (95% CI)GRADE quality of evidenceRelegation factors

Xiao Chao 2016 [18]7SMD = –1.16, 95% CI (–1.66, –0.66)Very low①②④⑤
Lu RuLing et al. 2018 [20]18MD = –1.84, 95% CI (–1.98, –1.70)Very low①②⑤
Yuan BoChao 2019 [25]5MD = –6.72, 95% CI (–7.32, –6.13)Very low①④⑤
Ji Lin 2019 [26]23SMD = –0.55, 95% CI (–0.74, –0.37)Low①④
Xie Peng Peng et al 2019 [27]13WMD = –0.95, 95% CI (–1.41, –0.52)Very low①②④
ZhongYizheng et al. 2019 [28]9SMD = –1.24, 95% CI (–1.39, –1.08)Very low①②④
Dong YuFang 2020 [29]39SMD = –0.38, 95% CI (–0.59, –0.16)Very low①②④
Li Nan et al. 2020 [30]5SMD = 1.67, 95% CI (–1.97, –1.37)Very low①②④
Lin BeiBei 2020 [32]17SMD = –0.78, 95% CI (–1.22, –0.34)Very low①②④
Chen JinMing et al. 2020 [33]2MD = 7.55, 95% CI (2.05, 13.04)Very low①②④⑤

Note. CI: confidence interval; MD: mean difference; SMD: standardized mean difference; WMD: weighted mean difference; ①: limitation; ②: inconsistency; ③: indirectness; ④: publication bias; ⑤: imprecision.